Natera, Inc. (NTRA)

Market Cap	29.04B +42.4%
Revenue (ttm)	2.31B +35.9%
Net Income	-208.16M
EPS	-1.52
Shares Out	141.73M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	808,762
Open	206.34
Previous Close	207.98
Day's Range	203.14 - 208.32
52-Week Range	125.38 - 256.36
Beta	1.68
Analysts	Strong Buy
Price Target	259.07 (+26.46%)
Earnings Date	May 7, 2026

About NTRA

Natera, Inc., a diagnostics company, engages in the development and commercialization of molecular testing services worldwide. It offers Signatera, a personalized ctDNA blood test for MRD assessment, early recurrence monitoring, and evaluation of treatment response in patients previously diagnosed with cancer; Latitude, a blood-based MRD test for colorectal cancer; Altera, a tissue based comprehensive genomic profiling test; and Empower, a hereditary cancer screening test. The company also provides Panorama, a non-invasive prenatal test; Horizo...

• Industry: Diagnostics & Research
• Sector: Healthcare
• IPO Date: Jul 2, 2015
• Employees: 6,140
• Stock Exchange: NASDAQ
• Ticker Symbol: NTRA
• Website: https://www.natera.com

Financial Performance

In 2025, Natera's revenue was $2.31 billion, an increase of 35.90% compared to the previous year's $1.70 billion. Losses were -$208.16 million, 9.31% more than in 2024.

Analyst Summary

According to 14 analysts, the average rating for NTRA stock is "Strong Buy." The 12-month stock price target is $259.07, which is an increase of 26.46% from the latest price.

Price Target

$259.07

(26.46% upside)

Analyst Consensus: Strong Buy